Careers  |  Sign In  |  Register  |   Twitter

Eylea Improves Vision in DME Patients Better Than Laser Surgery

Reuters reports that Regeneron Pharmaceuticals’sEylea significantly improved vision in patients with diabetic macular edema (DME) compared to laser surgery in two late-stage clinical trials.” Eylea has been approved for use against wet age-related macular edema, but these results are “paving the way for an expanded approval of the sight-saving medicine.” In two studies, patients either received Eylea monthly or bi-monthly after 5 monthly injections. In one trial, after one year of treatment the group receiving monthly injections showed the most improvement in a test of identifying letters on an eye chart (12.5 more letters), followed by the bi-monthly group (10.7 more letters), and then the group receiving treatment by laser photocoagulation (0.2 more letters). Results were similar in the second trial.

Read the article published by Reuters.